More Than 500 Clinical Practice Guidelines Now Available On-line

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 3
Volume 8
Issue 3

WASHINGTON-A new Internet library of clinical practice guidelines enables physicians to quickly examine hundreds of sets of treatment recommendations and to compare and contrast different guidelines. The National Guideline Clearinghouse (www.guideline.gov) went on-line in mid-January. The website was developed by HHS’ Agency for Health Care Policy Research, the American Medical Association, and the American Association for Health Plans. More than 500 clinical practice guidelines were put into the database initially, and others will be added.

WASHINGTON—A new Internet library of clinical practice guidelines enables physicians to quickly examine hundreds of sets of treatment recommendations and to compare and contrast different guidelines. The National Guideline Clearinghouse (www.guideline.gov) went on-line in mid-January. The website was developed by HHS’ Agency for Health Care Policy Research, the American Medical Association, and the American Association for Health Plans. More than 500 clinical practice guidelines were put into the database initially, and others will be added.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content